A high rate of mutation sets a strong foundation for the development of resistance to antiviral drugs. However, the ubiquitous presence of drug resistance mutations in the HBV population does not explain variations in the rate and specific types of drug resistance among patients. These variations can be explained by consideration of coevolution among individual sites in the HBV genome, viral variants and subpopulations, as well as coevolution between the entire intrahost HBV population and the host. The concept of coevolution offers a more complete framework for understanding drug resistance.
HBV is a small enveloped virus. The HBV genome is a partially double-stranded DNA of approximately 3,200 base pairs [1] that replicates by reverse transcription of its pregenomic RNA using the virus-encoded polymerase, which contains four functional domains [2, 3] . The most common treatment option for patients with chronic hepatitis B (CHB) is therapy with inhibitors of the HBV reverse transcriptase. However, continuous therapy can lead to the development of drug resistance and in some cases to multidrug resistance mutations within the HBV genome [4, 5] , which significantly reduces the treatment options of the affected patients and could lead to severe liver disease [6] .
There are several factors affecting the development of drug resistance in HBV-infected patients. These include the nature of the drug, genetic barrier to resistance, HBV viral load and genotype, HBV intrahost heterogeneity, hepatitis B e antigen (HBeAg) serostatus, host body mass index and serum alanine aminotransferase activity [5] . It is commonly accepted that a combination of the host and viral factors determines effectiveness of the specific therapy. The rate of emergence of drug-resistant HBV variants varies for different drugs [7, 8] . For example, >80% of HBV-infected patients develop resistance to lamivudine after 5 years on therapy, whereas only 1.2% of patients develop resistance to entecavir after 6 years of treatment [5] . Although the association between specific drugs and the rate of drug resistance is clear, the variation in the outcome of therapy in different patients treated with the same drug is less understood [5, 7] . It is not immediately clear, for example, why HBV becomes resistant to lamivudine in 14-32% of patients during the first year of treatment, whereas approximately 20% of patients do not have a detectable level of HBV after 5 years of treatment [5] .
In recent years, significant efforts have been made to understand factors affecting the rate of development of antiviral drug resistance and to prevent or, at least, reduce the risk of resistance. Drug resistance is usually interpreted in terms of survival and improvement of fitness of individual viral genomes afforded through direct phenotypic effects of drug resistance mutations [9] [10] [11] [12] without regard to the complex coordination that occurs between genetic traits shaping viral evolution. The present review considers the influence of genome-wide patterns of substitutions, interactions between viral variants and virus-host interactions in the course of chronic HBV infection on the development of drug resistance.
Frequency of substitutions
Genomic replication through an RNA intermediate has significant consequences for HBV evolution and development of drug resistance. Rapid evolution of RNA viruses is frequently explained by their high mutation rates. The rate of observed substitutions for HBV [13] falls in the range of 10 -4 -10 -5 substitutions per site per year, which is similar to the estimates for many RNA viruses [14] . The high rates of substitutions are attributed to the lack of the proofreading activity in RNA polymerases and RNA-dependent DNA polymerases [14, 15] .
For HBV, such a high substitution rate results in 0.1-1.0 substitutions per genome during each replication cycle [16] . As a result, numerous closely related Introduction variants of the viral genome can be found in infected hosts [1, 4, 15, 17] . HBV has a very rapid turnover during infection, with 10 11 -10 13 virions produced and cleared per day [18, 19] . It is not rare that HBV populations reach 10   10   -10 12 viral particles [20, 21] within a few weeks of infection starting from a small founder population transmitted to the host. This extensive population expansion can be achieved through a rapid succession of replication cycles of HBV genomes in infected hosts and thus generates frequent opportunities for each viral genomic site to mutate. Except for strongly deleterious mutations, many substitutions persist in the HBV population for a sufficient period of time for the mutant genome to acquire a second mutation. Because the probability of the reverse mutation is much lower than a mutation at sites in the other parts of the genome, viral genomes should frequently experience substitutions at >1 site, with a significant proportion of substitutions occurring in the mutant genomes.
A high rate of mutations and coexistence of numerous genomic variants that contain basically all possible combinations of double or even triple mutations provide a fertile ground for a rapid genetic response to variations in the host environment and for development of drug resistance [17, 18, 22] . However, the extent of presentation of individual mutations, although fundamentally crucial, is not sufficient for explaining variation in outcomes of therapy, which can range from rapid establishment of drug-resistant mutants in the HBV population to complete suppression of HBV infection [5, 7, 8, 12] . Assuming that the mutation rate is similar for all wild-type HBV strains and therefore the probability of presentation of mutations causing drug resistance are similar for all HBV lineages, some other factors must exist to exert a significant effect on the capacity of mutations to alter HBV phenotype. The frequent occurrence of combinations of mutations in the HBV genome is one of these factors.
Epistasis
Introduction of >1 mutation into viral genomes creates conditions for interaction between mutations. Epistasis is the dependence of phenotypic effects of one mutation on a mutation at another genomic site. In other words, phenotypic presentation of mutations depends on the genetic background into which such mutation occurs. Epistatic interactions between sites could significantly modify the strength and direction of selection acting at individual sites and therefore play a very important role in evolution [23] [24] [25] [26] [27] [28] [29] .
A hypothetical example of epistatic interactions between genomic sites and the effects of such interactions on fitness and evolutionary path or mutational trajectory is shown in Figure 1 . The genomic region with sequence 5′-G-G-G-G-3′ contains two sites, a and b. This region generates a double-stranded structure with a partially complementary sequence 5′-C-A-C-C-3′ (shown at the top of Figure 1A , underneath sequence 5′-GGGG-3′) located somewhere in the RNA molecule. The model in this example assumes that this double-stranded structure is functionally important and therefore strongly affects fitness. Thus, any reduction in the complementary interactions of this region should lead to reduction in fitness, and any mutation that causes such reduction should be considered as deleterious. The effects of two mutations, one at site a (G to A) and another at site b (G to T), on fitness of this hypothetical genetic system are different. Mutation at site a converts haplotype a 1 b 1 to a 2 b 1 and reduces complementary interactions. Thus, this mutation has a deleterious effect on fitness. The second mutation at site b restores the double-stranded structure in haplotype a 2 b 2 and, thus, can be considered as a beneficial mutation that compensates for the deleterious effect of the mutation at site a. However, if a mutation at site b occurs first, it does not reduce complementary interactions in haplotype a 1 b 2 and, consequently, does not have any effect on fitness of the system; therefore, it should be considered neutral. A second mutation at site a generates haplotype a 2 b 2 , which has fitness equal to haplotypes a 1 b 1 and a 1 b 2 , and therefore is neutral.
The order in which mutations occur at these two sites produces two different phenotypic trajectories, with path 'ab' following through decrease to restoration of fitness, and path 'ba' having no effect on fitness. Depending on the path, mutation at site a can be deleterious or selectively neutral, and mutation at site b can be beneficial or neutral. However, if the increase in stability of the double-stranded structure formed by haplotype a 1 b 2 results in fitness reduction, the phenotypic trajectory of path 'ba' should follow the trajectory of path 'ab'. In this case, both mutations at sites a and b of the original haplotype a 1 b 1 are deleterious, and each negative phenotypic effect can be reduced with mutation at the second site. Such interaction between mutations that reduces phenotypic expression of individual mutations is defined as antagonistic epistasis, which is opposite to synergistic epistasis that increases fitness effects of individual mutations.
The important observation from this model is that mutation at one site could change the intensity and direction of selection at another genomic site. For example, most l-nucleoside-resistant HBV strains contain the secondary substitutions, rt80V/I, rtI169T, rtV173L, rtT184G/S, rtS202I and rtQ215S in the HBV pol in addition to the primary drug resistance substitutions, rtM204V/I, rtL180M and rtA181T/N [5] . The primary substitutions have a dual effect on HBV fitness. They strongly facilitate resistance of the HBV polymerase to the inhibitory effect of the drug and, therefore, should be considered as beneficial mutations. However, the very same substitutions reduce viral replication and therefore exert a deleterious effect. This effect can, however, be mitigated by the secondary substitutions [5, 8] . Taking into consideration a low prevalence of the secondary mutations in the wild-type HBV population, it is reasonable to presume that all these mutations do not have a similar beneficial effect on HBV replication in the absence of the primary drug-resistant mutation, and are either neutral or deleterious. Thus, compensatory relationships between l-nucleoside resistance mutations could be viewed as antagonistic epistasis between deleterious mutations. The occurrence of the primary drugresistant mutation changes the direction of selection at the secondary sites from neutral or negative to positive. This compensation is, however, efficient only in the presence of l-nucleosides. The last observation highlights a definitive role of changes in the viral environment in forming epistatic connectivity within the HBV genome.
Epistasis in viral genomes
Although epistatic interactions between sites could be antagonistic, synergistic or multiplicative (independent), it was shown that such simple genetic systems as RNA viruses generally display antagonistic epistasis and therefore mutations combined together in viral genomes usually produce smaller phenotypic effects than expected from phenotypic effects of individual mutations [30, 31] . Antagonistic epistasis reduces the effectiveness of purging deleterious mutations and significantly contributes to mutational robustness of viral genomes [32, 33] . Thus, epistatic interactions assist in maintaining mutations and therefore quasispecies diversity in the viral population. A high rate of mutation places significant demands on viral genomes to tolerate deleterious mutations. Mutational robustness, defined as indifference of viral phenotypes to genetic variations in the genome, is intrinsically associated with the extent of antagonistic epistasis [32] [33] [34] .
Antagonistic epistasis between deleterious mutations frequently described in terms of compensatory mutations has a profound effect on the development of drug resistance [4, 5, 8, 9] . In addition to counteracting detrimental fitness effects caused by primary drug resistance mutations, as in the discussed earlier example of the HBV l-nucleoside resistance, antagonistic epistasis promotes persistence of potential drug resistance mutations even in the absence of the drug-selection pressure. However, the extent of such epistatic interactions should strongly depend on the genetic composition of the HBV population carried in the chronically infected host, with some viral genomes providing a genetic background conducive to more efficient mutation retention than other genomes.
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Antagonistic epistasis also reduces the extent of phenotypic expression for beneficial mutations and thus could hinder selection for drug-resistant phenotype. Again, this effect should strongly depend on the genetic background of the HBV genome in which drug resistance mutations occur.
Interference between beneficial mutations
The slow kinetics of emerging drug resistance is attributed to the mechanism of the HBV genome replication and persistence of HBV covalently closed circular DNA in infected hepatocytes [5, 35, 36] . Thus, differences in replication capacity between HBV strains could contribute to the variation of the rate of development of drug resistance observed in different patients. Although important, it is not the only virological factor that can introduce variation in drug resistance. The aforementioned effect of antagonistic epistasis between beneficial mutations on selection for drug resistance is another potentially important factor that should be taken into consideration.
The evolutionary effect that selection at one locus imposes on other loci has been noted since the dawn of population genetics. Interference between beneficial mutations was shown to result in the reduction of the probability of fixation of one beneficial mutation in the presence of another beneficial mutation. In other words, selection at more than one site should cause an overall reduction in the effectiveness of selection [37, 38] . The extent of this interference depends on selection intensity (mean and variance), the initial frequency of mutants (mutation rate), transition time to mutation fixation, size of the population and environmental conditions, and increases with genetic linkage between sites under selection [37, [39] [40] [41] [42] [43] . The reduction of the overall effectiveness of selection resulting from linkage between sites under selection is known as the 'Hill-Robertson effect' [44] .
Interference between beneficial mutations could have very important consequences for the development of drug resistance. Adaptation to new environmental conditions, such as the presence of inhibitors of viral replication, is associated with fixation of beneficial mutations that are being randomly produced. Because of high mutation rates, HBV establishes large populations containing a mixture of beneficial mutations in infected hosts. It should be noted that although the drug selection pressure is probably the most dominant selection factor acting on HBV in patients on antiviral therapy, the HBV population experiences many other strong selection pressures during chronic infections, such as specific immunological responses. Thus, a variety of advantageous mutations could arise at the same time in different viral genomes (that is, different genetic backgrounds), creating conditions for competition between these mutations. Such competition between beneficial mutations simultaneously segregating in the same population in different genomes has been dubbed as clonal interference [38] . Using evolving vesicular stomatitis virus populations of different sizes, it was observed that clonal interference could modulate the rate of viral adaptation, which reaches a plateau with increase in the population size. Higher population fitness can be achieved as population size and mutation rates increase [42] .
Although interference between advantageous mutations reduces overall effectiveness of selection, it provides a mechanism for a beneficial mutation to be rated against the genetic background, thus assisting in fixation of mutations with large adaptive effects. Together with epistasis, effects of mutational interference within and between genomes coordinate adaptive viral evolution at the level of individual genomes as well as the level of quasispecies populations. Coevolution generates linkages between substitutions and increases the probability of fixation of beneficial mutations according to their compatibility with the genetic background under the current environmental conditions, making substitutions appear in coordinated groups and shaping the sequence space occupied by the entire viral population. Thus, the evolutionary history of the viral population during infection, and especially chronic infection, might affect the probability of fixation of beneficial mutations such as drug resistance mutations.
Another important corollary of mutational interference is that by reducing the overall effectiveness of selection and making many weakly advantageous mutations effectively neutral, it increases the strength of genetic drift and slows down adaptive evolution [37, 38, 44] . This effect of interference between mutations has recently been observed for HIV escape mutations [45] . It is known that cytotoxic T-cells (CTL) produce a strong selection pressure on intrahost HIV evolution [46] . CTL-escape mutations can usually be detected within a few months after initiation of HIV infection [47] . However, the appearance of escape mutations at some epitopes is significantly delayed or cannot be detected [48] . Simulation experiments using standard population genetics assumptions regarding population size, subdivision, selection, discrete generations and recombination revealed that the time required for escape mutants to be detected is significantly affected by selection, mutation rate, effective population size and the presence of other beneficial mutations in the HIV population [45] . The time for the advantageous mutants requiring >1 escape or drug resistance mutation should be even longer than for mutants requiring a single mutation [45] . This is an additional factor contributing to the genetic barrier to resistance.
Global epistatic connectivity
Analysis of mutations affording resistance to nucleotide and nucleoside inhibitors of the HBV polymerase activity is usually confined to a small region of HBV genome encoding the major domains of reverse transcriptase [49, 50] . However, as was shown recently for HCV, many genomic sites have epistatic connections across the entire genome [51, 52] . Epistatic connectivity between HCV sites can be organized into a complex scale-free network, with some sites sharing connections with many other sites from different parts of the HCV genome and many sites having only a very few connections in the network [52] . A small number of highly connected sites exert a strong global impact on the state of the entire genome, whereas many other sites affect the state of the network to a smaller degree. These important findings emphasize that the contribution of every genomic site to viral evolution should additionally be ranked in accordance with its role in the network.
Global epistatic connectivity between sites reflects a significant role of coordinated evolution in facilitating viral adaptation to the host environment. Coordinated substitutions emerge during coevolution of different genomic sites. A selection pressure at one site transmits according to the degree of connectivity through the network to all other sites; therefore, a selection pressure acting on the site with a high global connectivity will affect states of many other sites within a given genome. Although the global epistatic connectivity of the primary and secondary drug resistance HBV mutations is yet to be investigated, it is conceivable that sites in the active centre of the HBV reverse transcriptase have extensive connections across the genome. In support of this supposition, many sites of the HCV nonstructural proteins including polymerase were found to have a very broad connectivity in the network of coordinated substitutions [52] . Accordingly, the drug resistance mutations might have a detectable global effect on HBV genome.
The topology and strength of connections in networks of coordinated substitutions are shaped by the intensity and specificity of selection pressures and therefore should depend on the size of viral population and nature of interactions with the host environment. For example, a decrease in the effective population size resulting from bottleneck or subdivision of the viral population should relax epistatic connectivity between sites, whereas changes in the host environment affecting viral fitness, such as specific immune responses or presence of drug, could modify relationships between sites in the network. These changes in selection pressures affecting the entire network should involve connectivity of drug resistance sites; therefore, the state of viral population and the stage of chronic infection should potentially contribute to the rate of the drug resistance development. Thus, factors such as the HBV viral load and HBeAg status that are known to affect the predisposition to drug resistance [5] should be reflected in epistatic connectivity between sites across the entire HBV genome.
Quasispecies
The development of viral drug resistance is frequently viewed as an example of 'survival of the fittest', thus emphasizing importance of individual fitness in order to overcome detrimental effects of drugs. Viral populations do not consist of a single variant, but rather exist as a 'cloud' of closely related viral variants or quasispecies linked to each other by mutations [53, 54] . Although applicability of the quasispecies concept to viruses is contended [55] , the most important properties of quasispecies have been experimentally demonstrated at least in some viral models [6, 56, 57] . Existence of quasispecies might be understood in the light of the mutation-selection balance under a high mutation rate. A high rate of mutation generates coupling between different members of quasispecies through mutations, such that each variant can be converted through a single mutation to another variant. A pure genetic linkage through mutations between members of quasispecies creates many important features pertinent to viral evolution and drug resistance.
It was observed in simulation experiments that, at the high mutation rate, the fastest replicating variant loses its advantage because the mutational coupling between variants becomes stronger than selection for an individual variant when the quasispecies forms [58] . In this condition, selection acts on the entire quasispecies rather than individual variants. The high mutation rate becomes a strong selection pressure and adaptation to frequent mutations leads to development of mutational robustness. The affected sequence variants might produce less progeny (lower fitness), but do not lose their capacity for propagation with acquisition of mutations (mutational robustness). Thus, at the high mutation rate, lower-fitness variants have a strong support from their mutational neighborhood and outcompete higher-fitness variants. This results in a broad population of sequence variants occupying a flat adaptive peak in the fitness landscape. This effect, termed 'survival of the flattest' [59, 60] , emphasizes that fitness of quasispecies is greatly determined at the population level rather than by individual variants.
The 'survival of the flattest' hypothesis, directly associated with the concept of mutational robustness [61, 62] , was experimentally confirmed on populations of the vesicular stomatitis RNA virus [57, 63] and plant viroid species [56] . Population genetics theory predicts that mutational robustness can only be efficiently selected at a high rate of mutation [59, 64] . Robustness can significantly affect the mean fitness of quasispecies population at high mutation rate or low population size [65] . As was discussed above, mutational robustness provides a broad genetic background for drug resistance mutations and suggests that fitness effects of these mutations should be considered at the level of the population of viral variants rather than at the level of the individual virus.
Cooperation
In addition to the mutational coupling as a form of support between viral sequence variants, the presence of viral quasispecies in infected hosts generates conditions for various interactions between viral variants and facilitates development of cooperation. Cooperation is a social behaviour that benefits another member of a species [66] , and it is only infrequently viewed by virologists as related to viruses. The nature of viral cooperation can be understood from the consideration of each viral variant existing in the presence of other variants, which, in addition to the host factors, constitute an important part of the viral environment and, therefore, act as a strong selection pressure.
Among the four major forms of social behaviour [66, 67] , selfishness and mutual benefit can be intuitively explained by selection pressures acting to improve individual fitness. Two other forms, altruism and spite, can, however, be derived only through consideration of indirect fitness and kin selection [68, 69] . Selection for traits beneficial to the fitness of relatives called kin selection is based on the concept of indirect fitness, which is a fitness component gained through aiding the reproduction of other genetically close (kin) members of the population [69] . Kin selection provides an explanation for altruistic cooperation between genetically close organisms and has been expressed in a very simple form, as rb-c>0, by Hamilton [70, 71] in his seminal works. It states that the altruism is favoured when fitness benefit (b) to the recipient weighted by the genetic relatedness (r) of the recipient to the actor (or the primary provider of the action) is greater than the cost to the actor (c). Thus, the evolutionary success of an individual organism in addition to its own fitness (direct fitness) depends on the fitness contribution from other kin members (indirect fitness).
Both altruistic and spiteful behaviour reduce fitness of the actor. However, altruism of the actor benefits the recipient, whereas spiteful action negatively affects the recipient fitness [66, 67] . Interaction between defective and viable viruses coinfecting the same cell presents an example of altruism wherein the defective virus supports its replication by acting as a recipient of functions provided by the viable virus (actor); for example, defective interfering particles [72] or, hypothetically, a drug-resistant variant supporting a drug-sensitive variant coinfecting the same cell in the drug presence. However, these roles can be reversed, at least in theory, when defective viral variants (actors) promote replication of the viable variants (recipients); for example, activation of HIV-infected quiescent T-cells by defective HIV [73] . Apoptosis could serve as an example of spite where the infected cell induces its own death to prevent the infecting virus from propagation and further dissemination within the host [74] . Spite can be explained in terms of indirect fitness effects benefitting a third party (indirect altruism). In the example of apoptosis, a third party would be other cells that benefit from the fitness loss of the infected cell and virus.
Selection pressures acting on individual viruses and entire viral population (multilevel selection) play a significant role in the intrahost viral evolution. Extensive genetic polymorphism of intrahost viral populations produced by the high mutation rate and maintained in the population through a variety of mechanisms (for example, epistasis, clonal interference, genetic drift, selection and population expansion) generates a similarly extensive variance in phenotypic expression of different virus-specific traits, thus providing an opportunity for the adaptive use of this variance and promoting coadaptation between and within viral subpopulations. Such coadaptation and cooperation between members of the viral population can be illustrated using the functional differentiation between HIV subpopulations in establishing intracellular productive replication [73] or complementation observed between poliovirus variants [75] . The last example is especially relevant because it supports the view that selection acts at the population level rather than on individual variants.
Viral variants evolve in infected hosts as a metapopulation composed of a large number of small subpopulations [76] . This population structure facilitates cooperative relationships at the level of subpopulations and the entire metapopulation. As a result, the population structure of viral variants does not simply reflect but also shapes selection pressures acting on the viral population. This consideration also applies to drug resistance, development of which can be strongly shaped by evolutionary processes occurring in the viral population.
Cooperative behaviour of viral variants has not been investigated in drug resistance settings. Some HBV drug resistance mutations, however, produce a very strong deleterious effect on replication that cannot be compensated through epistatic connectivity within affected genomes. In particular, the rtA181T substitution in the HBV pol generates a stop codon in the overlapping S gene, resulting in a defective envelope protein [77, 78] . The deleterious effect of this mutation cannot be reduced by another mutation in the same HBV genome. Nevertheless, because this substitution produces a drugresistant phenotype, thus having an advantageous effect on the genome carrying this mutation, the detrimental effect of this mutation on the envelope is compensated by drug-sensitive variants that encode a full-size envelope protein [77, 78] . The remarkable aspect of this cooperation is that both cooperating counterparts maintain their genetic features. Despite the fact that other drug resistance mutations are most probably present in the viral population because of the high mutation rate, the variant sensitive to the specific drug is not replaced by another drug-resistant mutant. Several factors such as a strong selection for cooperation between these HBV variants, clonal interference that increases transition time to fixation of beneficial mutations and epistatic connectivity that favours this particular drug resistance mutation could contribute to persistence of this complex drug resistance state of the HBV population. This example of compensation at the population level rather than individual genomes demonstrates the possibility of cooperative relationships between HBV variants and, more importantly, significance of the population structure for development of drug resistance Cooperation between and within viral subpopulations is an important factor of the intrahost viral evolution and most probably occurs to a certain extent during each HBV infection. Cooperative interactions between independently viable viral variants are difficult to recognize and study. However, examples of the cooperative relationship between defective and viable HBV variants can be frequently observed. A case in point is the persistence of complex HBV mutants, containing deletions/insertions in the core promoter and deletions in the C and preS genes, in the presence of wild-type HBV variants in long-term immunosuppressed renal transplant recipients who are chronically infected with HBV [79] . In this clinical setting, intrahost evolution results in HBV population containing sometimes approximately 90% of complex HBV mutants [80] . Although molecular evolutionary mechanisms responsible for the generation and maintenance of this complex HBV population is not known, it can be assumed that coevolution between these HBV variants is reflected in genetic composition of individual viral genomes and the entire intrahost population, and therefore affects the pattern of substitutions including drug resistance substitutions.
Host adaptation
Host demographic factors including race, gender and age, as well as host genetic factors play a very important role in defining outcomes of HBV infection [81, 82] . In turn, chronic viral infection has a profound effect on the host and modifies the intrahost environment by, for example, inducing the HBV-specific immune responses. This antagonistic host response to the infection has a significant effect on HBV fitness and, therefore, imposes a very strong selection pressure propelling the HBV intrahost evolution. Drug resistance, a special case of the HBV intrahost evolution, is also influenced by these immune responses, as suggested by the effect the HBeAg serostatus has on the rate of drug resistance development [5, 8] . The HBeAg seroconversion has been associated with generation of the heterogeneous intrahost HBV population [83, 84] . It was suggested that these changes in the HBV genome and structure of the viral population are the result of immune selection pressure [83] . According to the coevolution concept considered in this paper, the immune-escape mutations should induce readjustment of epistatic connectivity between many, or at least some, genomic sites and, therefore, modify selection pressures at these sites in HBV mutants remaining in circulation after the elimination of predominant HBV variants. Additionally, the decrease in the viral load associated with the HBeAg seroconversion [85, 86] results in decrease of the number of mutations circulating in HBV population and therefore reduces interference between beneficial mutations. As illustrated in previous sections (see Epistasis in viral genomes and Interference between beneficial mutations), these effects could change dynamics of presentation of many mutations, including those responsible for the drug resistance phenotype.
Chronic viral infections exact a heavy toll on host fitness. The establishment of chronic infection indicates that host defence mechanisms have failed to clear the virus. The extensive viral propagation and infection of a large number of the host cells during chronic infection change the direction of host fitness effects of the virus-specific immune responses. For example, CTL contribute to improvement of host fitness at the onset of viral infections. However, with the increasing number of infected cells during chronic infection, CTL reduce host fitness by eliminating many infected cells thereby damaging the host. To avoid this damage, the immune system produces specialized regulatory T-cells for suppression of antiviral T-cell responses [87] . The HBV-specific induction of regulatory T-cells prevents excessive immunopathological damage to the host and simultaneously facilitates establishment of persistent HBV infection [88] . HBV seems to exploit this host mechanism damping the immune-related damage to establish long-term chronic infections [88] .
Immune selection is usually considered as a dominant force shaping evolution of viruses. However, during chronic viral infections virus-specific immune responses become powerful selection pressures acting on the host as well. In the particular case of CHB, immune selection changes the clonal composition of liver [89, 90] . Hepatocyte turnover through cell death and proliferation plays an important role in resolution of acute infections and progression of chronic HBV infections. Immune selection acting on HBV-infected cells leads to the clonal expansion of hepatocytes resistant to HBV infection and the emergence of HBV mutants that reduce this immune selection pressure on the infected hepatocytes [91, 92] .
Directionality of intrahost evolution
'Arms race' is a frequently evoked concept describing virus-host relationships during infection. It implies constant antagonistic interactions between the viral and host genetic systems. However, as was noted earlier, there is a great deal of virus-host coadaptation in chronic HBV infection, which causes reduction in the intensity of antagonistic relationships. The interaction between HBV and its environment changes during chronic infection towards a less antagonistic coexistence, implying a directionality to virus-host coadaptation.
The interaction between HBV and host does not only shape the HBV intrahost evolution but also elicits strong adaptive reactions from the host. These reactions can differ considerably between acute and chronic infections. HBV induces adaptive changes in the host environment and is forced to adapt to these changes in order to survive. This continuous recursive process, however, follows a certain path. The natural history of HBV chronic infection has well-defined stages [21, 93] . Each stage is associated with regular changes in the intrahost environment, for example, seroconversion to different antigens, and is characterized by specific selection pressures acting on HBV and host. For example, the transition from the immunotolerant to immuno elimination phase of CHB was associated with increased presentation of mutations [83, 84] and decrease in the viral titre [85, 86] . As was already discussed, both of these parameters could significantly affect the dynamics of the intrahost HBV evolution. This regularity of intrahost events provides direction to the HBV intrahost evolution. There are many simple factors that might contribute to this directionality, including the duration of HBV infection itself, as ageing in the host is associated with reduction in strength of the immune system [94, 95] .
Another important factor contributing to directionality of HBV evolution is a decrease in the viral replicative space during chronic infection, with this space being defined as the number of cells available for viral infection. In addition to clonal expansion of hepatocytes resistant to HBV infection, resistance to superinfection can also contribute to the reduction of this space [96] . The phenomenon of resistance to superinfection with the same virus, called superinfection exclusion, is common among viruses [97, 98] . Both factors lead to the decrease in the number of potential targets for infection. The extent of this decrease depends on the hepatocyte turnover and state of chronic infection. The consequent reduction in replicative space can contribute to variation in the rate of drug resistance. For example, the average period of time before emergence of lamivudine-resistant HBV variants was longer in non-transplant than in transplant patients [50] , with the rates of drug resistance being higher in transplant than in non-transplant patients [99] .
Besides limiting the size of the HBV intrahost population, shrinking the replicative space affects the composition of this population by protecting HBV variants already established in the host from being rapidly replaced by more fit variants that might emerge during infection [100] . In addition to clonal interference and epistasis, such variation in the size of replicative space influences the probability of fixation of beneficial mutations.
Conclusions
The intricate interdependence and coordination between individual genetic traits, leading to coevolution of these traits, define HBV evolution. However, they have not been thoroughly assessed in the context of the development of drug resistance. Viral adaptation is strongly affected by numerous viral and host factors that themselves tend to change in the course of infection in a certain regular manner, thus exerting directionality to coevolution. The regular molecular processes induced by the virus in the host define HBV as species and shape intrahost HBV evolution. Antiviral therapy, not being a part of these regular processes, poses an additional and unusual challenge to the capacity of HBV to adapt. The rate of drug resistance and specific genetic composition of drug-resistant mutants depend on the state of coevolution among individual sites within the viral genome and among viral variants as well as between the entire viral intrahost population and host environment. Therefore, the disposition towards drug resistance should vary depending on epistatic connectivity within genomes, the state of the intrahost HBV population and the stage of HBV chronic infection.
The model of drug resistance based on the high rate of mutation and individual fitness effects of mutations provides a rational explanation for the escape of viral populations from strong selection pressures produced by therapy or vaccine. However, providing the general explanation for the phenomenon itself, this model does not clearly instruct on approaches to overcome the HBV capacity to adapt. The existing HBV therapy is very efficient in some patients, indicating that the available drugs are capable of the complete suppression of HBV infection. Failure to inhibit HBV replication in other patients led to the recognition that some specific parameters of HBV infection play an important role in defining the efficacy of therapy [5, 8] . Consideration of HBV drug resistance in the light of coevolution opens a novel avenue for understanding these parameters and should help in improving efficacy of the existing therapies and guiding toward the rational development of novel efficient drugs. The concept of coevolution is integrative by its nature. It requires consideration of viral heterogeneity and evolution in relation to many host and viral factors, some of which are discussed in this paper. Provided with quantitative measures for factors most contributing to the development of drug resistance, a model built on coevolution should be accurately predictive and could be used to identify strategies for the most successful application of existing therapies and to develop novel therapeutic approaches.
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